ABSTRACT
Background Zoonotic P. knowlesi and P. cynomolgi symptomatic and asymptomatic infections occur across endemic areas of Southeast Asia. Most infections are low-parasitemia, with an unknown proportion below routine microscopy detection thresholds. Molecular surveillance tools optimizing the limit of detection (LOD) would allow more accurate estimates of zoonotic malaria prevalence.
Methods An established ultra-sensitive Plasmodium genus quantitative-PCR (qPCR) assay targeting the 18S rRNA gene underwent LOD evaluation with and without reverse transcription (RT) for P. knowlesi, P. cynomolgi and P. vivax using total nucleic acid preserved (DNA/RNA ShieldTM) isolates and archived dried blood spots (DBS). LODs for selected P. knowlesi-specific assays, and reference P. vivax- and P. cynomolgi-specific assays were determined with RT. Assay specificities were assessed using clinical malaria samples and malaria-negative controls.
Results The use of reverse transcription improved Plasmodium species detection by up to 10,000-fold (Plasmodium genus), 2759-fold (P. knowlesi), 1000-fold (P. vivax) and 10-fold (P. cynomolgi). The median LOD with RT for the Kamau et al. Plasmodium genus RT-qPCR assay was ≤0.0002 parasites/µL for P. knowlesi and 0.002 parasites/µL for both P. cynomolgi and P. vivax. The LODs with RT for P. knowlesi-specific PCRs were: Imwong et al. 18S rRNA (0.0007 parasites/µL); Divis et al. real-time 18S rRNA (0.0002 parasites/µL); Lubis et al. hemi-nested SICAvar (1.1 parasites/µL) and Lee et al. nested 18S rRNA (11 parasites/µL). The LOD for P. vivax- and P. cynomolgi-specific assays with RT were 0.02 and 0.20 parasites/µL respectively. For DBS P. knowlesi samples the median LOD for the Plasmodium genus qPCR with RT was 0.08, and without RT was 19.89 parasites/uL (249-fold change); no LOD improvement was demonstrated in DBS archived beyond 6 years. The Plasmodium genus and P. knowlesi-assays were 100% specific for Plasmodium species and P. knowlesi detection, respectively, from 190 clinical infections and 48 healthy controls. Reference P. vivax-specific primers demonstrated known cross-reactivity with P. cynomolgi.
Conclusion Our findings support the use of an 18S rRNA Plasmodium genus qPCR and species-specific nested PCR protocol with RT for highly-sensitive surveillance of zoonotic and human Plasmodium species infections.
Author Summary The monkey malaria parasite Plasmodium knowlesi has been found to increasingly infect humans across Southeast Asia via the bite of it’s anopheline mosquito vectors. Human infections with a similar monkey parasite, Plasmodium cynomologi, have also been reported. The diagnostic tools commonly used to detect these malaria species are often unable to detect very low-level infections. We aimed to to improve surveillance detection tools and blood sample collection methods to detect these zoonotic malaria species and understand the extent of transmission and the burden of disease. This study validated and compared the use of molecular laboratory assays targeting these species. We found that with the use of reverse transcription, large improvements in the limit of detection were possible, by up to 10,000-fold for initial malaria screening, and up to 2759-fold for specific P. knowlesi detection. Findings from this study support the use of ultrasensitive detection tools to improve surveillance approaches to emerging zoonotic malaria species.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the ZOOMAL project, funded through the Australian Centre for International Agricultural Research and Indo-Pacific Centre for Health Security, DFAT, Australian Government (#LS-2019-116), the National Institutes of Health, USA (#R01AI160457-01), and DOD-DHA-Global Emerging Infections Surveillance program project P0097_22_N2.). Funding support was also through the National Health and Medical Research Council, Australia (Grant Numbers #1037304 and #1045156, fellowship to NMA [#1042072], Emerging Leadership 2 Investigator Grants to MJG [#2017436] and BEB [#2016792]), and the Ministry of Health, Malaysia (#BP00500/117/1002) awarded to GSR.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Sample collection and diagnostic evaluation were approved as part of prospective malaria studies by the Medical Research and Ethics Committee (MREC), Ministry of Health Malaysia (NMRR-10-754-6684, NMRR-19-4109-52172 and NMRR-19-3229-49967), Universitas Sumatera Utara, Indonesia (#723/KEP/USU/2021) and by the Menzies School of Health Research, Australia (HREC-2010-1431 and HREC-2022-4417) in accordance with all applicable Federal and other regulations governing the protection of human subject research.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript